WO1995016454A1 - Method for treatment of papulo-pustules and comedones of the skin - Google Patents
Method for treatment of papulo-pustules and comedones of the skin Download PDFInfo
- Publication number
- WO1995016454A1 WO1995016454A1 PCT/US1994/014536 US9414536W WO9516454A1 WO 1995016454 A1 WO1995016454 A1 WO 1995016454A1 US 9414536 W US9414536 W US 9414536W WO 9516454 A1 WO9516454 A1 WO 9516454A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- papulo
- solution
- hydrogen peroxide
- fruit
- Prior art date
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 79
- 206010037888 Rash pustular Diseases 0.000 title claims abstract description 46
- 208000029561 pustule Diseases 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims description 33
- 238000011282 treatment Methods 0.000 title abstract description 17
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 78
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 59
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000002253 acid Substances 0.000 claims abstract description 38
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 36
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 25
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 21
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 21
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 230000003902 lesion Effects 0.000 claims abstract description 10
- 208000000069 hyperpigmentation Diseases 0.000 claims abstract description 9
- 230000003810 hyperpigmentation Effects 0.000 claims abstract description 9
- 230000037390 scarring Effects 0.000 claims abstract description 8
- 241001303601 Rosacea Species 0.000 claims abstract description 6
- 201000004700 rosacea Diseases 0.000 claims abstract description 6
- 206010016936 Folliculitis Diseases 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000002995 comedolytic effect Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 206010000502 Acne cosmetica Diseases 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 229940107700 pyruvic acid Drugs 0.000 claims description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 2
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 241000132456 Haplocarpha Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 11
- 241000186427 Cutibacterium acnes Species 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 238000001035 drying Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010033733 Papule Diseases 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 4
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 241000212749 Zesius chrysomallus Species 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- -1 glycolic Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- DANVPDNHSWUGAN-UHFFFAOYSA-M potassium;benzoyl benzenecarboperoxoate;hydrogen sulfate;quinolin-8-ol Chemical compound [K+].OS([O-])(=O)=O.C1=CN=C2C(O)=CC=CC2=C1.C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 DANVPDNHSWUGAN-UHFFFAOYSA-M 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000513 Acne pustular Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
Definitions
- the present invention relates to the topical treatment of papulo-pustules (pimples) and comedones of the human face. More particularly, the invention is directed to a spot therapy for rapid drying up of the papulo-pustules, a method for reducing scarring and hyperpigmentation owing to 10 more rapid resorption of the papulo-pustules, and to spot therapy for the treatment of comedones .
- Papulo-pustules commonly known as pimples or zits
- a pustule is a soft pimple full of neutrophiles. It is yellow
- Pustules are not infections, but are non ⁇ specific inflammatory reactions involving the disruption of the lining walls of the sebaceous follicles of the face.
- a pustule ensues when a comedo ruptures, dumping horn, bacteria, yeasts, hairs and sebum into the dermis.
- a papule is a deeper, larger inflammatory reaction which is more solid, but is still mainly made up of neutrophiles. A papule is more likely to scar and leave a pigmented spot. Papules are also quite common in blacks, who
- Papules and pustules differ essentially only in degree, and both types of lesions may be covered by the term “papulo-pustules" or more simply “pimples.”
- Papulo-pustules are obvious and spring up rapidly in less than 24 hours and even overnight. They may be quite sore and tender. These pimples take about 7-10 days to resorb or dry up without treatment. However, after resorption they may leave a long-lasting red spot in whites and in blacks a dark pigmented spot (hyperpigmentation) which may last for many months. This also happens in other dark-skinned persons, such as Orientals, and is considered to be a disquieting cosmetic defect .
- Benzoyl peroxide is widely used to treat acne based on its antibacterial properties especially in suppressing P. acnes in follicles. It is applied to the entire face and is not used for spot therapy. However, its capacity to dry up existing pimples, even in 10 percent formulations, is very limited.
- Glycolic acid is popular in many cosmetics and skin care treatments as a natural fruit acid. It is also a well- known exfoliant, widely used for light peels by dermatologists. Fruit acids, such as glycolic, citric or lactic, may be helpful as topical agents for spot therapy, but must be used at 40 percent peeling concentrations, usually in a physician's office. These are the so-called alpha-hydroxy acids which are currently the rage in women's magazines. At 50-75% concentrations, glycolic acid and other fruit acids are used by dermatologists to give a full face peel. Lactic and glycolic acids at commercial OTC concentrations of 5-10 percent simply do not resolve pimples.
- Salicylic acid is a standard keratolytic in OTC products to treat comedones, and is a well-known exfoliant widely used in light peels by dermatologists. Salicylic acid also has some anti-inflammatory effect and is often incorporated into topical drugs to reduce inflammation.
- the Quinoderm patent is based upon killing P. acnes in the follicles using a cream, lotion or gel containing hydrogen peroxide and maintained at an acid pH.
- the L'Oreal patent involves an anhydrous solution of hydrogen peroxide applied to the entire face and specifically directed to killing P. acnes, the main organism in acne.
- the present invention has nothing to do with killing P. acnes.
- papulo-pustules may be rapidly resorbed by a spot therapy which comprises application to the exterior surface of the papulo-pustules of an aqueous solution comprising hydrogen peroxide and optionally at least one of a fruit acid and salicylic acid, in an amount, at a concentration and at a frequency sufficient to effect resorption of the papulo-pustules within two to three days.
- the solution contains about 3 to 6 weight percent hydrogen peroxide, with or without a fruit acid such as glycolic acid and citric acid, present in a concentration equivalent to about 2 to 4 weight percent glycolic acid, and with or without 2 to 4 weight percent salicylic acid, and may be dabbed on the papulo-pustule in an amount sufficient to wet the surface 2 to 3 times daily for 1 to 3 days.
- the method of the invention is also effective to substantially lessen or avoid hyperpigmentation and scarring after resorption of the papulo-pustules.
- Another aspect of the invention is a method for spot therapy of comedones, including both open and closed comedones, comprising topically applying to the exterior surface of the comedone an aqueous solution as described above containing hydrogen peroxide, a fruit acid and salicylic acid, said solution being applied in an amount, at a concentration and at a frequency sufficient to provide a comedolytic effect within about 7 to 20 days of therapy.
- the solution may be dabbed on the comedone in an amount sufficient to wet the surface two or three times daily for about 10 to 20 days .
- Hydrogen peroxide is a well known antiseptic and bleaching agent . It is an OTC product which can be purchased readily for disinfection and cleaning of wounds. It is generally safe and carries no risks. However, the present invention is not based upon a debridement, cleaning or disinfection action, but rather a resorption and drying up of the papulo-pustules.
- the present invention has nothing to do with the antibacterial effect of hydrogen peroxide.
- hydrogen peroxide kills P. acnes in vitro
- I have found it to be completely ineffective in vivo.
- up to 10 weight percent aqueous solutions of hydrogen peroxide have been applied to skin with acne, but no reduction of the follicular population of P. acnes has been found.
- the mode of action of hydrogen peroxide in this instance is entirely different.
- Hydrogen peroxide is not used in OTC preparations for acne.
- benzoyl peroxide does suppress P. acnes in vivo and is commercially useful .
- the oxidizing property of hydrogen peroxide is probably important in the mechanism of the present invention. After application to the skin, the site whitens and gets frothy, which is almost certainly due to the release of oxygen. The latter is a highly reactive chemical which combines quickly and avidly with skin proteins, resulting in their coagulation. This is the probable mechanism of whitening. While concentrations of hydrogen peroxide in water up to about 10 percent by weight (w/v) have been found quite effective and act very quickly to resorb the papulo-pustules, such high concentrations are unnecessary and cause too much stinging and burning. Preferably, the concentration of hydrogen peroxide in water should be about 3-6 weight percent, and more preferably about 3-5 weight percent. This is a stable solution and requires no buffering.
- hydrogen peroxide is co-formulated with one or more of the adjuvants salicylic acid and fruit acid, wherein exemplary fruit acids are glycolic acid, citric acid, lactic acid, malic acid, pyruvic acid and mixtures thereof. Glycolic acid is a preferred fruit acid.
- said co- formulation affords benefits unavailable from the use of hydrogen peroxide alone.
- the presence of one or more adjuvants serves to stabilize the hydrogen peroxide, and therefore provides a longer self-life to the composition.
- the adjuvant (s) promote penetration of the composition into the tissue, and hence promote greater therapeutic effects. Deep-seated papules and even cysts are more likely to respond to the co-formulation of the invention. It is also observed that the co-formulation promotes faster resorption of the papulo-pustules by, it is hypothesized, speeding up the drying effect of the hydrogen peroxide.
- the co-formulation is more comedolytic than a formulation lacking the adjuvants of the invention: hydrogen peroxide alone has slight, if any, comedolytic effect. It is observed that when the composition of the invention is applied daily to large, ugly open comedones (also known as blackheads), the horny plugs fall out within 7 to 14 days. Closed comedones are also receptive to the inventive method, although the treatment typically takes longer, for example, up to about 20 days. The removal of comedones by spot therapy is a considerable improvement cosmetically. Elimination of comedones is prophylactic because all the inflammatory lesions in acne develop from the rupture of comedones.
- the combination of hydrogen peroxide, fruit acid and salicylic acid can be applied to the entire face as a general treatment for acne, as well as to selected areas which tend to be more prone to infection.
- the fruit acid is glycolic acid and it is present at a concentration of about 2 to 4 weight percent.
- said fruit acid(s) should be present in an amount equivalent to about 2 to 4 weight percent glycolic acid.
- Combinations of glycolic acid and one or more other fruit acids may also be used in the inventive co-formulations, where said combinations are present in a concentration equivalent to about 2 to 4 weight percent glycolic acid.
- salicylic acid is present in a concentration of about 2 to 4 weight percent.
- each adjuvant While higher adjuvant concentrations, for example above 5%, may be used, excessive peeling may result as well as chemical burns and irritation. Thus, it is preferred to keep each adjuvant at a concentration below 5 weight percent.
- a composition having either glycolic acid or salicylic acid present in the range of about 2 to 4 weight percent is only a mild, tolerable irritant. Of course, where fruit acid(s) weaker or less effective than glycolic acid are used, concentrations of such fruit acid may be higher than 5 weight percent .
- Either fruit acid or salicylic acid may be used alone with the hydrogen peroxide, however preferably both adjuvants are co-formulated with hydrogen peroxide in order to provide optimal stability and other desirable effects.
- Glycolic acid is a preferred fruit acid.
- Salicylic acid and fruit acids such as glycolic acid, are compatible with each other and with hydrogen peroxide, so that no special means are necessary in preparing the co-formulations.
- Thickeners, such as methyl cellulose, or gelling agents can be added, if desired, to facilitate delivery to the skin.
- the aqueous hydrogen peroxide solution with or without adjuvant may be simply applied in an amount sufficient to wet the surface of the papulo-pustule. Since the pimple will immediately turn white upon application of the solution, the whitening is a good indicator of whether enough solution has been applied. That is, just enough need be applied to produce whitening of the pimple. However, an excess will do no harm, and exactitude is not required. Any appropriate means of application which will wet the surface of the papulo-pustule may be used. A cotton tipped rod or stick has been found suitable, and preferred would be a cotton or felt tipped applicator which could be carried around in a small vial in a purse or pocket, since frequent application is desirable.
- the hydrogen peroxide solution with or without adjuvant should preferably be applied by dabbing or by other means on the papulo-pustules 2 to 3 times daily for 1 to 3 days, 2 to 3 days in the case of hydrogen peroxide alone.
- the pimples immediately turn white and then progressively dry up. The rapid resorption of the pimples is not only cosmetically useful, but also encourages compliance with the spot therapy treatment, since the patient sees the whitening and can perceive the drying process taking place.
- the hydrogen peroxide solution of the invention with or without adjuvant can preferably be applied as soon as the first red spot appears, which patients readily recognize. However, fully developed papulo-pustules will also dry up quickly. One can treat 20-30 pimples at a time, but usually the patient will be treating many fewer than this. While pimples will resolve spontaneously over a period of a week or more without treatment, early application is important in order to lessen scarring and hyperpigmentation which follow tissue-destroying inflammatory reactions. • Thus, the longer the pimple remains, the greater will be the hyperpigmentation and scarring.
- Another feature of this invention is prophylaxis which rapidly converts the earliest detectable lesion, usually only a red, flat spot, into a small pustule. This can happen in as little as 1 to 2 hours. Continued applications bring about a rapid drying up of these diminutive, abortive pustules, thus reducing their sequelae.
- This spot therapy as a two-stage process: (1) rapid evolution into an abortive pimple and (2) rapid resorption.
- Application to the earliest lesions will prevent the development of a larger papulo-pustule and reduce the possibility of scarring and hyperpigmentation.
- Papulo-pustular acne is increasing in post- menopausal women, particularly as they compete in the marketplace. They need a convenient way to abort pimples and to look well groomed.
- the spot therapy of the present invention provides a convenient, swift and exact targeting of the problem pimples .
- the treatments of the present invention are applicable to all types of papulo-pustules or pimples, they have been found to be particularly useful in the spot therapy of papulo-pustules in patients suffering from adolescent acne, post-adolescent female acne, peri-menopausal acne, acne cosmetica and in rosacea.
- follicular pustules of whatever origin, including bacterial infections will also resorb quickly when treated with the solution.
- the treatments of the present invention using hydrogen peroxide in combination with the above adjuvants are also applicable to comedones, including both open and closed comedones.
- spot therapy comprising topically applying to the exterior surface of a comedone an aqueous solution containing hydrogen peroxide, fruit acid and salicylic acid according to the invention
- a comedolytic effect is observed within 7 to 20 days of therapy.
- Glycolic acid is a preferred fruit acid according to this aspect of the invention.
- Open comedones generally require about 7 to 14 days of spot therapy, while closed comedones typically require spot therapy for about 10 to 20 days in order to achieve exfoliation of the horny plugs.
- each application of solution comprises dabbing with an applicator in an amount sufficient to wet the surface of the comedone with said solution, and the inventive therapy comprises topical applications of the solution to the comedone 2 to 3 times daily.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU14382/95A AU1438295A (en) | 1993-12-17 | 1994-12-15 | Method for treatment of papulo-pustules and comedones of the skin |
| EP95905978A EP0739209A4 (en) | 1993-12-17 | 1994-12-15 | Method for treatment of papulo-pustules and comedones of the skin |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16984393A | 1993-12-17 | 1993-12-17 | |
| US169,843 | 1993-12-17 | ||
| US25024894A | 1994-05-27 | 1994-05-27 | |
| US250,248 | 1994-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1995016454A1 true WO1995016454A1 (en) | 1995-06-22 |
Family
ID=26865436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/014536 WO1995016454A1 (en) | 1993-12-17 | 1994-12-15 | Method for treatment of papulo-pustules and comedones of the skin |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0739209A4 (en) |
| AU (1) | AU1438295A (en) |
| CA (1) | CA2179188A1 (en) |
| CZ (1) | CZ178196A3 (en) |
| WO (1) | WO1995016454A1 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031420A1 (en) * | 1997-01-16 | 1998-07-23 | Btg International Limited | Antibacterial medical devices |
| WO1999037295A1 (en) * | 1998-01-21 | 1999-07-29 | Devillez Richard L | Method and composition for skin treatment |
| WO2000002593A3 (en) * | 1998-07-09 | 2000-08-24 | Benac Sa | Cleansing and treating lotion for treating comedones |
| EP1100366A4 (en) * | 1998-07-09 | 2002-07-03 | Curelight Ltd | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
| US6472432B1 (en) * | 1997-11-17 | 2002-10-29 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
| WO2002074290A3 (en) * | 2001-03-15 | 2004-02-19 | Agis Ind 1983 Ltd | Dermatological preparations containing a nsaid |
| WO2005025486A3 (en) * | 2003-09-13 | 2005-05-06 | Boots Healthcare Int Ltd | Skincare compositions comprising salicyclic acid |
| WO2005079745A1 (en) * | 2004-02-19 | 2005-09-01 | Reckitt & Colman (Overseas) Limited | Skincare compositions comprising salicylic acid |
| WO2005079746A1 (en) * | 2004-02-19 | 2005-09-01 | Reckitt & Colman (Overseas) Limited | Skincare compositions |
| EP1100454A4 (en) * | 1998-07-31 | 2006-09-20 | Howard Murad | Pharmaceutical compositions and methods for managing skin conditions |
| US7179389B2 (en) | 2000-08-04 | 2007-02-20 | Mcclung James E | Method of using a composition for treatment in a waste treatment or sewage system |
| US7198634B2 (en) | 1999-07-07 | 2007-04-03 | Curelight Ltd. | Phototherapeutic treatment of skin conditions |
| US7501388B2 (en) | 2000-08-04 | 2009-03-10 | Mcclung James E | Method of using a composition for disinfection and/or sterilization |
| GB2589862A (en) * | 2019-12-09 | 2021-06-16 | Institute Of Tech Sligo | Antimicrobial composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315883B (en) * | 2020-11-24 | 2023-01-06 | 哈尔滨敷尔佳科技股份有限公司 | Skin care composition for controlling oil and removing acne and preparation and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4428933A (en) * | 1982-08-02 | 1984-01-31 | King John R | Composition for treating acne, method of manufacturing said composition, and method of treating skin |
| US4557935A (en) * | 1981-03-17 | 1985-12-10 | Biogram Ab | Germicidal composition |
| US4826681A (en) * | 1985-02-26 | 1989-05-02 | L'oreal | Anhydrous solution of hydrogen peroxide in an organic solvent and the use of the same in therapeutic and cosmetic formulations |
| US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
| US5242433A (en) * | 1992-12-07 | 1993-09-07 | Creative Products Resource Associates, Ltd. | Packaging system with in-tandem applicator pads for topical drug delivery |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363815A (en) * | 1975-07-23 | 1982-12-14 | Yu Ruey J | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions |
| GB2068225B (en) * | 1980-06-09 | 1983-12-14 | Quinodern Ltd | Dermatological compositions containing hydrogen peroxide |
| US4485091A (en) * | 1980-07-15 | 1984-11-27 | Quinoderm Limited | Dermatological compositions |
| US4438102A (en) * | 1982-08-10 | 1984-03-20 | Ciro's Touch, Ltd. | Method of promoting tissue growth |
| IL71865A (en) * | 1984-05-17 | 1984-11-30 | Haviva Rivkin | Purifying liquid cleanser comprising antiseptics |
-
1994
- 1994-12-15 CZ CZ961781A patent/CZ178196A3/en unknown
- 1994-12-15 WO PCT/US1994/014536 patent/WO1995016454A1/en not_active Application Discontinuation
- 1994-12-15 AU AU14382/95A patent/AU1438295A/en not_active Abandoned
- 1994-12-15 EP EP95905978A patent/EP0739209A4/en not_active Withdrawn
- 1994-12-15 CA CA 2179188 patent/CA2179188A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4557935A (en) * | 1981-03-17 | 1985-12-10 | Biogram Ab | Germicidal composition |
| US4428933A (en) * | 1982-08-02 | 1984-01-31 | King John R | Composition for treating acne, method of manufacturing said composition, and method of treating skin |
| US4826681A (en) * | 1985-02-26 | 1989-05-02 | L'oreal | Anhydrous solution of hydrogen peroxide in an organic solvent and the use of the same in therapeutic and cosmetic formulations |
| US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
| US5242433A (en) * | 1992-12-07 | 1993-09-07 | Creative Products Resource Associates, Ltd. | Packaging system with in-tandem applicator pads for topical drug delivery |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0739209A4 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031420A1 (en) * | 1997-01-16 | 1998-07-23 | Btg International Limited | Antibacterial medical devices |
| US6472432B1 (en) * | 1997-11-17 | 2002-10-29 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
| US6586472B2 (en) * | 1997-11-17 | 2003-07-01 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
| WO1999037295A1 (en) * | 1998-01-21 | 1999-07-29 | Devillez Richard L | Method and composition for skin treatment |
| WO2000002593A3 (en) * | 1998-07-09 | 2000-08-24 | Benac Sa | Cleansing and treating lotion for treating comedones |
| EP1100366A4 (en) * | 1998-07-09 | 2002-07-03 | Curelight Ltd | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
| US6835202B2 (en) | 1998-07-09 | 2004-12-28 | Curelight Ltd. | Apparatus and method for high energy photodynamic therapy of acne vulgaris and seborrhea |
| EP1100454A4 (en) * | 1998-07-31 | 2006-09-20 | Howard Murad | Pharmaceutical compositions and methods for managing skin conditions |
| US7198634B2 (en) | 1999-07-07 | 2007-04-03 | Curelight Ltd. | Phototherapeutic treatment of skin conditions |
| US7179389B2 (en) | 2000-08-04 | 2007-02-20 | Mcclung James E | Method of using a composition for treatment in a waste treatment or sewage system |
| US7501388B2 (en) | 2000-08-04 | 2009-03-10 | Mcclung James E | Method of using a composition for disinfection and/or sterilization |
| WO2002074290A3 (en) * | 2001-03-15 | 2004-02-19 | Agis Ind 1983 Ltd | Dermatological preparations containing a nsaid |
| WO2005025486A3 (en) * | 2003-09-13 | 2005-05-06 | Boots Healthcare Int Ltd | Skincare compositions comprising salicyclic acid |
| JP2007505093A (en) * | 2003-09-13 | 2007-03-08 | ブーツ ヘルスケア インターナショナル リミテッド | Skin care compositions and methods |
| WO2005079746A1 (en) * | 2004-02-19 | 2005-09-01 | Reckitt & Colman (Overseas) Limited | Skincare compositions |
| WO2005079745A1 (en) * | 2004-02-19 | 2005-09-01 | Reckitt & Colman (Overseas) Limited | Skincare compositions comprising salicylic acid |
| GB2589862A (en) * | 2019-12-09 | 2021-06-16 | Institute Of Tech Sligo | Antimicrobial composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2179188A1 (en) | 1995-06-22 |
| AU1438295A (en) | 1995-07-03 |
| EP0739209A1 (en) | 1996-10-30 |
| CZ178196A3 (en) | 1997-03-12 |
| EP0739209A4 (en) | 2000-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220288134A1 (en) | Composition, system and method for treating skin | |
| US9962402B2 (en) | Healing composition for topical application | |
| EP0739209A1 (en) | Method for treatment of papulo-pustules and comedones of the skin | |
| US3821370A (en) | Topical composition for treating seborrheic keratosis | |
| Collins | The chemical peel | |
| NZ223558A (en) | Acne treatment composition | |
| KR100673044B1 (en) | Topical Compositions for Transdermal Administration | |
| ES2441440T3 (en) | Product for the treatment of skin and mucous membranes, and associated preparation method | |
| Zachariae | Dermabrasion in Darier's disease | |
| US5973010A (en) | Composition for healing skin wounds | |
| Shalita | Topical acne therapy | |
| CA2126704C (en) | Dermatological compositions and methods for the treatment of skin therewith | |
| US12156927B2 (en) | Formulation for odontological and dermatological use containing trchloroacetate salts and hydroxyacids | |
| RU2190388C1 (en) | Preparation on base of tea tree oil (versions) | |
| RU2826643C2 (en) | Compositions for odontological and dermatological use, containing trichloroacetate salts and hydroxyacids | |
| Mozafarpoor et al. | Fractional ablative Er: YAG laser therapy in a patient with chronic recessive dystrophic epidermolysis bullosa: a case report and review of literature | |
| JP2006517924A (en) | Odorless formulation for treating mucosal disconnection | |
| Cahn | Current status of acne treatment | |
| KR20010025824A (en) | Cosmetic compositions for the skin having pimples thereon | |
| Baran et al. | Treatment of Common Nail Disorders | |
| DYSTROPHIES | BRITTLE NAILS | |
| Shalita | Topical Therapy of Acne | |
| NZ721272B2 (en) | Composition, system and method for treating skin | |
| NZ759509B2 (en) | Composition, system and method for treating skin | |
| Kon-Knox, CP,* Scott, SA** & Popovich | Treating acne vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2179188 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PV1996-1781 Country of ref document: CZ Ref document number: 1995905978 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 278226 Country of ref document: NZ |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1995905978 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: PV1996-1781 Country of ref document: CZ |
|
| WWR | Wipo information: refused in national office |
Ref document number: PV1996-1781 Country of ref document: CZ |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1995905978 Country of ref document: EP |